Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-I experience

Journal of the American College of Cardiology

Volumn 28, Issue 7, 1997, Pages 1661-1669

  Woodfield, Scott L ^a   Lundergan, Conor F ^a   Reiner, Jonathan S ^a   Greenhouse, Samuel W ^a   Thompson, Mark A ^a   Rohrbeck, Steven C ^a   Deychak, Yuri ^a   Simoons, Maarten L ^b   Califf, Robert M ^c   Topol, Eric J ^d   Ross, Allan M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUKE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART VENTRICLE FUNCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; CORONARY ANGIOGRAPHY; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; STREPTOKINASE; STROKE VOLUME; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0030462332     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00397-X     Document Type: Article

References (46)

1. Steiner G. Diabetes and atherosclerosis: an overview. Diabetes 1981;30 Suppl 2:1-7.
2. Bradley RF, Bryfogle JW. Survival of diabetic patients after myocardial infarction. Am J Med 1956;20:207-16.
3. Partamian JO, Bradley RF. Acute myocardial infarction in 258 cases of diabetes: immediate mortality and 5 year survival. N Engl J Med 1965;273: 455-61.
4. Soler NG, Bennett MA, Pentecost BL, et al. Myocardial infarction in diabetics. Q J Med 1975;44:125-32.
5. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1974;23:105-11.
6. Kereiakes DJ. Myocardial infarction in the diabetic patient. Clin Cardiol 1985;8:446-50.
7. Gundersen T, Kjekshus JK. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-90.
8. Molstad P, Nustad M. Acute myocardial infarction in diabetic patients. Acta Med Scand 1987;222:433-7.
9. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8:230-4.
10. Stone PW, Muller JE, Hartwell T, et al. The effect of diabetes on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary artery disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 1989;14:49-57.
11. Jaffee AS, Spadaro JJ, Schectman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984;108:31-7.
12. Smith JW, Marcus FI, Serokman R, for the Multicenter Post Infarction Research Group. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984;54:718-21.
13. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction: interaction of diabetes with other preinfarction risk factors. Diabetes 1989; 38:350-7.
14. Cooper RS, Pacold IV, Fords ES. Age related differences in case-fatality rates among diabetic patients with myocardial infarction. Acta Med Scand 1991;14:903-8.
15. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993;21:920-5.
16. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after myocardial infarction. N Engl J Med 1993;329:1615-22.
17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
18. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison of intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-54.
19. Dodge HT, Sandler H, Ballew DW, Lord JD. The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J 1960;60:762-6.
20. Bolson EL, Kliman S, Sheehan F, Dodge HT. Left ventricular segmental wall motion - a new method using local direction information. In: Computers in Cardiology. Long Beach (CA): IEEE Computer Society Press, 1981:245-8.
21. Freund RJ, Littell RC. The SAS System for Regression. 2nd ed. Cary, (NC): SAS Institute, Inc., 1991.
22. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation 1995;91:1659-68.
23. Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion: GUSTO-I Investigators. Circulation 1995;91:1923-8.
24. Ostermann H, van der Loo J. Factors of the hemostatic system in diabetic patients. Haemostasis 1986;16:386-416.
25. Breddin H, Krezywanek H, Altoff P, et al. PARD: platelet activation as a risk factor in diabetes: results of a prospective study. Horm Metab Res 1985;15 Suppl:63-8.
26. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type-II diabetes mellitus. N Engl J Med 1990;322:1769-74.
27. Badawi H, El-Sawy M, Mikhail M, Nomier A, Tewfik S. Platelets, coagulation and fibrinolysis in diabetic and nondiabetic patients with quiescent coronary heart disease. Angiology 1970;21:511-9.
28. Schneider DJ, Nordt TK, Bosel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1-7.
29. Sane DC, Stump DC, Topol EJ, et al. Correlation between plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991;65:275-9.
30. Barbash GI, Hod H, Roth A, Miller HI, et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct related artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-5.
31. Gary RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993;70:530-6.
32. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients; fact or fiction? Circulation 1978;57:133-6.
33. Crofford OB. Diabetes control and complications. Annu Rev Med 1995;46: 267-79.
34. Fein F. Diabetic cardiomyopathy. Diabetes Care 1990;13:1169-79.
35. Dash R, Johnson R, Dinsmore R. Cardiomyopathic syndrome due to coronary artery disease. II: increased prevalence in patients with diabetes mellitus: a matched pair analysis. Br Heart J 1977;39:740-7.
36. Shapiro LM. Echocardiographic features of impaired ventricular function in diabetes mellitus. Br Heart J 1982;47:439-44.
37. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy due to familial diabetes mellitus. J Clin Invest 1977;60:885-9.
38. Regan TJ, Patel N, Al-Adli N, Lyons M. Altered collagen glycation in the diabetic heart [abstract]. Clin Res 1992;40:220A.
39. Regan TJ, Ettinger PO, Kahan MI, et al. Altered myocardial function and metabolism in chronic diabetes mellitus without ischemia in dogs. Circ Res 1974;33:232-7.
40. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Circulation 1992;85:1254-64.
41. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-83.
42. Ulvenstam G, Aberg A, Bergstrand R, et al. Long term prognosis after myocardial infarction in men with diabetes. Diabetes 1985;34:7870-92.
43. Herlitz J, Malmberg K, Karlson B, et al. Mortality and morbidity during a five year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31-8.
44. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259-64.
45. Barbash G, White HD, Modan M, Van De Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:707-13.
46. Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-94.